Author

A. Heard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

A. Gruszczynska· 1 shared A. Khanna· 1 shared B. A. Wadugu· 1 shared C. A. Miller· 1 shared C. L. Shirai· 1 shared D. DeNardo· 1 shared D. L. Fei· 1 shared G. Hogg· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Gruszczynska

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction

M. E. Selli, J. H. Landmann, M. Terekhova, J. Lattin, A. Heard, Y.-S. Hsu, T.-C. Chang, J. M. Warrington, H. Ha, N. Kingston, G. Hogg, M. Slade, M. M. Berrien-Elliot, M. Foster, S. Kersting-Schadek, , N. Singh

This study identifies that chronic activation of 41BB-based CARs leads to a novel T cell dysfunction state, distinct from exhaustion, which can be mitigated by disrupting FOXO3.

bioRxiv · Jan 26, 2023 · PreprintImmunology

U2AF1 is a haplo-essential gene required for cancer cell survival

B. A. Wadugu, A. Heard, S. N. Srivatsan, M. O. Alberti, M. Ndonwi, J. Bradley, J. Shao, T. Ahmed, C. L. Shirai, A. Khanna, D. L. Fei, C. A. Miller, T. A. Graubert, M. J. Walter

This study shows that U2AF1 is a haplo-essential gene for cancer cell survival, as mutant cells depend on residual wild-type U2AF1 for viability and are sensitive to its reduction.

Journal of Clinical Investigation · Nov 1, 2021Peer-reviewedCancer Biology